Canaccord Genuity Initiates Sage Therapeutics With Buy


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


Analysts at Canaccord Genuity initiated coverage on shares of Sage Therapeutics (NASDAQ: SAGE) with a Buy rating.The target price for Sage Therapeutics is set to $40.Sage Therapeutics' shares surged 4.73% to $34.98 in pre-market trading.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: InitiationAnalyst RatingsCanaccord Genuity